Fast Discharge After Acute Myocardial Infarction Discharge MI (DISCHARGE-MI)

March 11, 2026 updated by: Medical University Innsbruck

Fast Discharge After Acute Myocardial Infarction Discharge MI - A Randomized Multicenter Non Inferiority Trial

To evaluate the hypothesis that a fast discharge strategy (discharge at 24 [± 12] hours) following invasive management for acute myocardial infarction is non-inferior to standard of care (>36 hours) with respect to the risk of major adverse cardiovascular events (MACE) during follow-up.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The goal of this randomized, multicenter trial is to assess the safety of a fast discharge strategy following acute myocardial infarction as compared to standard of care. The trial will evaluate the hypothesis that a fast discharge strategy (discharge at 24 [± 12] hours) following invasive management of acute myocardial infarction is non-inferior to standard of care (discharge >36 hours) with respect to the risk of major adverse cardiovascular events at 12 months.

Study Type

Interventional

Enrollment (Estimated)

2070

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Austria
    • Lower Austria
    • Salzburg
      • Salzburg, Salzburg, Austria, 5020
        • Recruiting
        • Paracelsus Medical University Salzburg
        • Contact:
    • Schwarzach Im Pongau
      • Schwarzach im Pongau, Schwarzach Im Pongau, Austria, 5620
    • Styria
    • Tyrol
      • Innsbruck, Tyrol, Austria, 6020
        • Recruiting
        • Medical University of Innsbruck
        • Contact:
        • Contact:
        • Principal Investigator:
          • Martin Reindl, MD, PhD
        • Principal Investigator:
          • Sebastian J Reinstadler, MD, PhD
        • Sub-Investigator:
          • Ivan Lechner, MD, PhD
        • Sub-Investigator:
          • Alex Kaser, MD
    • Upper Austria
      • Wels, Upper Austria, Austria, 4600
    • Vorarlberg
      • Feldkirch, Vorarlberg, Austria, 6800
  • Germany

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Uncomplicated acute myocardial infarction (NSTEMI and STEMI) diagnosed according to the 2023 acute coronary syndrome guidelines of the ESC
  • Age ≥ 18 years at time of consent
  • Invasive management strategy and in case of PCI successful intervention of the culprit lesion defined by post-interventional TIMI 3 flow
  • Ability to understand and willingness to sign and date written informed consent

Exclusion Criteria:

  • Myocardial infarction complicated by cardiac arrest (out-of-hospital cardiac arrest/in-hospital cardiac arrest)
  • PCI-related complications (coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, allergic reaction grade ≥2, stroke/thromboembolism, access site complications including pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage and arterial dissection/occlusion or emboli)
  • Malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (< 50 beats per minute due to sinus node or atrioventricular conduction system abnormalities, second- /third-degree atrioventricular block) after PCI
  • Ongoing hemodynamic instability (systolic blood pressure <90 mmHg, elevated lactate concentrations, need for inotropes or vasopressors)
  • Ongoing respiratory instability defined by Killip class >I (rales, pulmonary edema)
  • Ongoing quantitative disorders of consciousness (somnolence, sopor, coma)
  • Acute kidney injury defined by Kidney Disease Improving Global Outcomes (KDIGO) stages 2 and 3
  • Pregnancy
  • Untreated critical non-culprit lesions requiring revascularization during index hospitalization not allowing fast discharge
  • Immobility/limited mobility or social circumstances that prevent fast discharge assessed by an interprofessional care team

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Fast discharge strategy
Fast discharge at 24 (+/-12) hours after invasive management of acute myocardial infarction.
Procedure: Fast discharge strategy
Patients undergoing invasive management after myocardial infarction will be discharged after 24 (+/- 12) hours.
No Intervention: Standard Care
Patients undergo a standard post-infarction care, with discharge at >36 hours after invasive management of acute myocardial infarction.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
MACE
Time Frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
MACE is defined as a composite of all-cause death, myocardial re-infarction and unscheduled cardiovascular re-hospitalization.
From the date of randomization until the first documented event during the follow-up period (up to 12 months).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
All cause death
Time Frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Death from any cause.
From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with myocardial re-infarction
Time Frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants experiencing myocardial re-infarction
From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with unscheduled cardiovascular re-hospitalization
Time Frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with unscheduled cardiovascular re-hospitalization
From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with Cardiovascular death
Time Frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants experiencing cardiovascular-related death
From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants hospitalized for heart failure
Time Frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants hospitalized for heart failure
From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants expiring hospitalization from any cause
Time Frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants expiring hospitalization from any cause
From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of patients experiencing a stroke
Time Frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of patients experiencing a stroke
From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with a bleeding event
Time Frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with a bleeding event
From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Healthcare costs per patient between randomization and 12 months
Time Frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
An economic evaluation will be conducted from the healthcare payer perspective. Direct healthcare costs, including intervention costs, hospitalizations, outpatient visits, diagnostic procedures, and concomitant medications, will be collected prospectively for each participant over the study period. Mean total healthcare costs per patient will be calculated and compared between study groups.
From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Length of hospital stay
Time Frame: From the date of randomization to the date of hospital discharge, for up to 100 days
Number of days in hospital from time of infarction to hospital discharge
From the date of randomization to the date of hospital discharge, for up to 100 days
Percentage of patients on guideline-directed therapy
Time Frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Percentage of patients on guideline-directed therapy
From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Infection
Time Frame: At 30 days
Infection leading to hospitalization
At 30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Medical University Innsbruck

Investigators

  • Principal Investigator: Martin Reindl, MD, PhD, Medical University Innsbruck
  • Principal Investigator: Sebastian J Reinstadler, MD, PhD, Medical University of Innsbruck

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2024

Primary Completion (Estimated)

December 31, 2029

Study Completion (Estimated)

December 31, 2029

Study Registration Dates

First Submitted

December 13, 2024

First Submitted That Met QC Criteria

December 19, 2024

First Posted (Actual)

December 20, 2024

Study Record Updates

Last Update Posted (Actual)

March 16, 2026

Last Update Submitted That Met QC Criteria

March 11, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1284/2024
  • 20241113-3609 (Other Identifier: Medical University Innsbruck)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Myocardial Infarction (AMI)

Clinical Trials on Fast discharge strategy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe